Skip to main content
Erschienen in:

15.03.2023 | case report

Alopecia associated with dimethyl fumarate treatment for multiple sclerosis

verfasst von: Ana Abičić, MD, Ivan Adamec, MD, PhD, Mario Habek, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 11-12/2023

Einloggen, um Zugang zu erhalten

Summary

After 2 weeks of treatment, a woman with multiple sclerosis treated with dimethyl fumarate developed alopecia. Considering the adverse events, the therapy was discontinued, leading to alopecia regression during the next 3 months. Although the precise mechanism has not been completely elucidated, glutathione depletion or downregulation of aerobic glycolysis are considered to be potential reasons for hair loss induction. The incidence and mechanism of this uncommon adverse reaction to dimethyl fumarate should be further investigated.
Literatur
1.
Zurück zum Zitat Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2015;76:243–54.CrossRef Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2015;76:243–54.CrossRef
3.
Zurück zum Zitat Losavio FA, Lucchini M, De Fino C, Mirabella M, Nociti V. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. Mult Scler Relat Disord. 2016;7:68–9.CrossRefPubMed Losavio FA, Lucchini M, De Fino C, Mirabella M, Nociti V. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis. Mult Scler Relat Disord. 2016;7:68–9.CrossRefPubMed
4.
Zurück zum Zitat di Nuzzo L, Orlando R, Nasca C, Nicoletti F. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther. 2014;8:555–68.PubMedPubMedCentral di Nuzzo L, Orlando R, Nasca C, Nicoletti F. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther. 2014;8:555–68.PubMedPubMedCentral
5.
Zurück zum Zitat Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360:449–53.CrossRefPubMedPubMedCentral Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360:449–53.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Purba TS, Berriche L, Paus R. Compartmentalised metabolic programmes in human anagen hair follicles: New targets to modulate epithelial stem cell behaviour, keratinocyte proliferation and hair follicle immune status? Exp Dermatol. 2021;30:645–51.CrossRefPubMed Purba TS, Berriche L, Paus R. Compartmentalised metabolic programmes in human anagen hair follicles: New targets to modulate epithelial stem cell behaviour, keratinocyte proliferation and hair follicle immune status? Exp Dermatol. 2021;30:645–51.CrossRefPubMed
7.
Zurück zum Zitat Lipparini R, Di Feliciantonio R, Randi V. Un caso di porfiria acuta intermittente a manifestazioni addominali e nervose e con alopecia generalizzata reversibile. Arch Patol Clin Med. 1965;42:45–52.PubMed Lipparini R, Di Feliciantonio R, Randi V. Un caso di porfiria acuta intermittente a manifestazioni addominali e nervose e con alopecia generalizzata reversibile. Arch Patol Clin Med. 1965;42:45–52.PubMed
8.
Zurück zum Zitat Chan A, de Seze J, Comabella M. Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs. 2016;30:41–51.CrossRefPubMedPubMedCentral Chan A, de Seze J, Comabella M. Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs. 2016;30:41–51.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Muehler A, Kohlhof H, Groeppel M, et al. The selective oral Immunomodulator vidofludimus in patients with active rheumatoid arthritis: safety results from the COMPONENT study. Drugs R D. 2019;19:351–66.CrossRefPubMedPubMedCentral Muehler A, Kohlhof H, Groeppel M, et al. The selective oral Immunomodulator vidofludimus in patients with active rheumatoid arthritis: safety results from the COMPONENT study. Drugs R D. 2019;19:351–66.CrossRefPubMedPubMedCentral
Metadaten
Titel
Alopecia associated with dimethyl fumarate treatment for multiple sclerosis
verfasst von
Ana Abičić, MD
Ivan Adamec, MD, PhD
Mario Habek, MD, PhD
Publikationsdatum
15.03.2023
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 11-12/2023
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-023-01007-7

Weitere Artikel der Ausgabe 11-12/2023

Wiener Medizinische Wochenschrift 11-12/2023 Zur Ausgabe

images in science and medicine

Giant cell epulis